Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70622 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Anna Sofie Buhl Rasmussen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Imatinib Mesylate, Hydroxycholesterols, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vissing Foundation, Danish Childhood Cancer Foundation, Director Michael Hermann Nielsen Foundation, section B.
Abstract (Originalsprache)
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling. The endogenous biomarker 4β‐hydroxycholesterol (4‐β‐OHC) has been proposed to reflect CYP3A4 activity, enabling proactive dose optimization. This study investigated 4‐β‐OHC as a CYP3A4 biomarker in leukaemia patients and its relationship with imatinib pharmacokinetics Methods A pharmacokinetic study included 19 patients with chronic myeloid leukaemia or acute lymphoblastic leukaemia receiving imatinib. Blood samples were collected over 24 h. Imatinib, N‐desmethyl imatinib, 4‐β‐OHC and 4α‐hydroxycholesterol (4‐α‐OHC) plasma concentrations were quantified by liquid chromatography–tandem mass spectrometry (LC–MS/MS), while total cholesterol was measured by clinical chemistry autoanalyser. CYP3A4 activity was estimated using the 4‐β‐OHC/cholesterol ratio. Genotyping of relevant CYP3A4/5 gene variants was carried out. Pharmacokinetic parameters were estimated using PKanalix software. Simple and multiple linear regressions were performed Results Nineteen patients were included with median age of 66 years (range 44–77). Pharmacokinetic parameters were comparable to prior reporting. The 4‐β‐OHC/cholesterol ratio showed a significant positive association with imatinib clearance, explaining 30% of variance. No significant association was found between CYP3A4 activity and N‐desmethyl‐imatinib area under the concentration time–curve (AUC)/imatinib AUC ratio. Single‐point sampling of imatinib at 3–4 h post‐dose correlated better with AUC 0 –24h than trough concentrations. CYP3A4/5 genotype assessment was limited by low patient numbers Conclusion This is the first study investigating 4‐β‐OHC as a biomarker for CYP3A4 activity in imatinib‐treated leukaemia patients, demonstrating clinically meaningful associations with imatinib clearance and supporting further development of this personalized therapy approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Pediatric Oncology Research Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Research Unit for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
- Molecular Unit, Department of Pathology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
ORCID-Profile: Anna Sofie Buhl Rasmussen, Cecilie Utke Rank, Christen Lykkegaard Andersen, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Tore Bjerregaard Stage, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff
Förderung
- Vissing Foundation
- Danish Childhood Cancer Foundation
- Director Michael Hermann Nielsen Foundation, section B
- Engineer Otto Christensen Foundation
- Manufacturer Einar Willumsen Memorial Foundation
- Vissing Fonden
- Børnecancerfonden
Zitieren
APA
Rasmussen, A. S. B., Koch, M. R., Rank, C. U., Andersen, C. L., Weimann, A., Thastrup, M., Yang, T., Lund, T. M., Christensen, I. J., Nielsen, F., Stage, T. B., Jensen, S. B., Andersen, M. K., Schmiegelow, K., & Dalhoff, K. (2026). Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70622
Vancouver
Rasmussen ASB, Koch MR, Rank CU, Andersen CL, Weimann A, Thastrup M, et al. Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70622
BibTeX
@article{Rasmussen2026,
author = {Rasmussen, Anna Sofie Buhl and Koch, Mathilde Rønne and Rank, Cecilie Utke and Andersen, Christen Lykkegaard and Weimann, Allan and Thastrup, Maria and Yang, Tianwu and Lund, Trine Meldgaard and Christensen, Ib Jarle and Nielsen, Flemming and Stage, Tore Bjerregaard and Jensen, Sara Bisgaard and Andersen, Mette Klarskov and Schmiegelow, Kjeld and Dalhoff, Kim},
title = {Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70622}
}
EUVIMED